<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>PURPOSE: CBL is a negative regulator of activated receptor tyrosine kinases (RTK) </plain></SENT>
<SENT sid="1" pm="."><plain>In this study, we determined the frequency of CBL mutations in <z:hpo ids='HP_0002488'>acute leukemias</z:hpo> and evaluated the oncogenic potential of mutant CBL </plain></SENT>
<SENT sid="2" pm="."><plain>EXPERIMENTAL DESIGN: The cDNA of 300 <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>)/<z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">MDS</z:e>) and <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (ALL) patients and 82 human leukemic cell lines was screened for aberrations in the linker and RING finger domain of CBL </plain></SENT>
<SENT sid="3" pm="."><plain>The oncogenic potential of identified mutants was evaluated in hematopoietic cells </plain></SENT>
<SENT sid="4" pm="."><plain>RESULTS: We identified 3 of 279 AML/MDS patients expressing CBL exon 8/9 deletion mutants </plain></SENT>
<SENT sid="5" pm="."><plain>Three of four cases at diagnosis expressed deleted transcripts missing exon 8 or exon 8/9 </plain></SENT>
<SENT sid="6" pm="."><plain>In remission samples a weak or no expression of mutant CBL was detected </plain></SENT>
<SENT sid="7" pm="."><plain>No aberrations were found in <z:mpath ids='MPATH_458'>normal</z:mpath> hematopoietic tissues </plain></SENT>
<SENT sid="8" pm="."><plain>One of 116 sequenced <z:e sem="disease" ids="C1332153" disease_type="Neoplastic Process" abbrv="">AML/MDS</z:e> cases carried a R420G missense mutation </plain></SENT>
<SENT sid="9" pm="."><plain><z:hpo ids='HP_0000001'>All</z:hpo> <z:e sem="disease" ids="C1332153" disease_type="Neoplastic Process" abbrv="">AML/MDS</z:e> patients with identified CBL mutants belonged to the core binding factor and 11q deletion <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> subtypes </plain></SENT>
<SENT sid="10" pm="."><plain>Functionally, CBL negatively regulated FMS-like tyrosine kinase 3 (FLT3) activity and interacted with human FLT3 via the autophosphorylation sites Y589 and Y599 and colocalized in vivo </plain></SENT>
<SENT sid="11" pm="."><plain>Expression of CBLDeltaexon8 and CBLDeltaexon8+9 in FLT3-WT-Ba/F3 cells induced growth factor-independent proliferation associated with autophosphorylation of FLT3 and activated the downstream targets signal transducer and activator of transcription 5 (STAT5) and protein kinase B (AKT) </plain></SENT>
<SENT sid="12" pm="."><plain>FLT3 ligand-dependent hyperproliferation of CBL mutant cells could be abrogated by treatment with the FLT3 PTK inhibitor PKC412 (midostaurin) </plain></SENT>
<SENT sid="13" pm="."><plain>CONCLUSION: CBL exon8/9 mutants occur in genetically defined <z:e sem="disease" ids="C1332153" disease_type="Neoplastic Process" abbrv="">AML/MDS</z:e> subtypes and transform hematopoietic cells by constitutively activating the FLT3 pathway </plain></SENT>
<SENT sid="14" pm="."><plain>This phenotype resembles the one of mutated RTKs and suggests that CBL mutant <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> patients might benefit from treatment with FLT3 PTK inhibitors </plain></SENT>
</text></document>